Akaal Pharma Pty Ltd has received approval for a Phase-2 clinical trial involving patients with atopic dermatitis.
Greater Shepparton, Victoria, Australia, 3rd May 2023. Akaal Pharma Pty Limited (Akaal) today announced that it has received regulatory approval from Drugs Controller General of India (DCGI) for a Phase-2 clinical study involving 150 participants to further evaluate the safety, tolerability, and efficacy of a topical formulation of AK-119 in atopic dermatitis participants with pruritus. … Read more